ADC Therapeutics Director Timothy Coughlin Receives 45,000 RSUs and Sells 12,600 Shares

This Form 4 filing reports equity transactions by Timothy Coughlin, a director of ADC Therapeutics SA. On June 1, 2026, Coughlin was granted 45,000 restricted stock units under the company's 2019 Equity Incentive Plan for his service as a director. These RSUs vest on the earlier of one year from the grant date or the date of the 2027 Annual Meeting of Shareholders, contingent on his continued service. Each RSU represents a right to receive one common share. On June 3, 2026, Coughlin disposed of 12,600 common shares at $3.08 per share, which were withheld by the company to satisfy tax withholding obligations related to the vesting of previously granted restricted share units. Following these transactions, Coughlin's direct ownership decreased from 85,000 to 72,400 common shares.